ReviewJournal of clinical hypertension (Greenwich, Conn.)2008
Renovascular hypertension: an update.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- 2024 Thai guidelines on the treatment of hypertension.Asian biomedicine : research, reviews and news · 2025Article
- Management of Renovascular Hypertension and Renal Denervation in Patients with Hypertension: An Italian Nationwide Survey.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2024Article
- Exome sequencing implicates ancestry-related Mendelian variation at SYNE1 in childhood-onset essential hypertension.JCI insight · 2024Article
- Percutaneous Transluminal Renal Angioplasty for Fibromuscular Dysplasia and Prognostic Risk Factors: A Retrospective Chinese Cohort Study.Journal of clinical medicine · 2022Article
- Evaluation of the presence of TRPC6 channels in human vessels: A pilot study using immunohistochemistry.Biomedical reports · 2022Article
- Resveratrol Supplants Captopril's Protective Effect on Cardiac Remodeling in a Hypertension Model Elicited by Renal Artery Stenosis.The Yale journal of biology and medicine · 2022Article
- An Outline of Renal Artery Stenosis Pathophysiology-A Narrative Review.Life (Basel, Switzerland) · 2021Review
- ATAmerican journal of physiology. Regulatory, integrative and comparative physiology · 2019Article
- Renal Artery Stenosis in Patients with Resistant Hypertension: Stent It or Not?Current hypertension reports · 2017Review
- Impact of Comorbidities on Acute Injury and Recovery in Preclinical Stroke Research: Focus on Hypertension and Diabetes.Translational stroke research · 2016Review
- Diagnostic and medical strategy for renovascular hypertension: report from a monocentric pediatric cohort.European journal of pediatrics · 2015Article
- Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension.Journal of translational medicine · 2014Article
- Physicians' perceptions and adherence to guidelines for the management of hypertension: a national, multicentre, prospective study.International journal of hypertension · 2012Article
- Lactobacillus fermentum ME-3 - an antimicrobial and antioxidative probiotic.Microbial ecology in health and disease · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renovascular hypertension, the most common remediable cause of elevated blood pressure, is a controversial topic, but most authorities agree on several principles. The absolute risk of renovascular hypertension for a specific patient can be estimated using only clinical information, thereby sparing many patients further expensive and potentially dangerous evaluations. Patients with a high absolute risk of renovascular hypertension should have angiography only if they are willing to undergo revascularization if warranted. A screening test (captopril renography, Doppler ultrasonography, magnetic resonance angiography, or computed tomography) is recommended for those with an intermediate absolute risk. Angioplasty should be offered to patients with fibromuscular dysplasia. Whether intensive medical therapy (including an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker) for atherosclerotic renovascular hypertension is improved by angioplasty plus stent placement may be answered by ongoing studies, the largest of which may be the National Institutes of Health-funded Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.